12/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
2:10 PM | Cormorant Asset Management, LP (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/12/2024
1:31 PM | EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024
8:33 AM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2024
7:54 AM | EyePoint Pharmaceuticals (Subject)
FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
| Form SC 13G | |
11/04/2024
10:57 AM | EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
|
10/31/2024
3:16 PM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
11:51 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
10/30/2024
3:20 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
4:17 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/23/2024
3:34 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
10/15/2024
10:58 AM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/21/2024
3:32 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/18/2024
11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
08/08/2024
3:42 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
08/08/2024
3:46 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/07/2024
6:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/26/2024
3:47 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
3:24 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:00 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:03 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:04 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/26/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
3:16 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/04/2024
3:28 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
3:22 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/16/2024
4:19 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/14/2024
3:39 PM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
9:12 AM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024
3:23 PM | Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/06/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Has Trump Finally Gone Too Far? (Ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks.
It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives.
But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars.
And here's the good news. Register For The Webinar To Discover |
05/01/2024
4:08 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
04/30/2024
7:53 PM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
04/22/2024
3:15 PM | Adage Capital Management, L.P. (Reporting)
Atchinson Robert (Reporting)
EyePoint Pharmaceuticals (Issuer)
Gross Phillip (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/02/2024
4:27 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/08/2024
12:53 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2024
4:37 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/04/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
6:01 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2024
8:08 PM | EyePoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
4:37 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:38 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:39 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
4:40 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
11:00 AM | EyePoint Pharmaceuticals (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024
6:54 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/06/2024
9:55 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SC 13G/A | |
02/05/2024
4:15 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
3:22 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/30/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:51 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
4:54 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:24 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
5:26 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:50 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2024
3:25 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:42 PM | EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/22/2024
3:19 PM | EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/16/2024
5:55 PM | EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
5:01 PM | EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/11/2024
4:33 PM | EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2024
3:53 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/09/2024
8:28 PM | EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:17 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:53 PM | ANDO GORAN (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:54 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:55 PM | EyePoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
7:56 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:04 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:07 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:09 PM | EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:11 PM | EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/09/2024
8:12 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2024
5:37 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4/A | |
01/02/2024
4:41 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Has Trump Finally Gone Too Far? (Ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks.
It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives.
But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars.
And here's the good news. Register For The Webinar To Discover |
